Fulltext present in this item

Thumbnail
Fulltext: 198072.pdf
Format: PDF
Description: publisher's version
Title: Disease duration as an indicator of the efficacy of liraglutide in patients with type 2 diabetes mellitus
Author(s): Wilbrink, F.J. ; Mudde, A.H.; Mulder, A.H.; Bhansing, K.J.
Publication year: 2018
Source: Journal of Diabetes Investigation, vol. 9, iss. 4, (2018), pp. 979-980
ISSN: 2040-1116
DOI: https://doi.org/10.1111/jdi.12857
Publication type: Article / Letter to editor

Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/198072   https://hdl.handle.net/2066/198072

Display more details
Subject: Radboudumc 5: Inflammatory diseases RIHS: Radboud Institute for Health Sciences
Tijdelijke code tbv inlezen publicaties Radboudumc - Alleen voor gebruik door Radboudumc
Organization: Internal Medicine
Rheumatology
Journal title:
Journal of Diabetes Investigation
Volume: vol. 9
Issue: iss. 4
Page start: p. 979
Page end: p. 980
Abstract:
Comment on the article of Usui et al. Retrospective cohort study of obese patients with type 2 diabetes mellitus (n = 69) demonstrates that the glucose-lowering effect of liraglutide as add on therapy to insulin relies on the remaining beta-cell function in type 2 diabetes. Shorter disease duration implies a more favourable prognosis for response on instantaneous substitution of insulin with liraglutide (HR 2.39 (95% CI: 1.20-4.76).

This item appears in the following Collection(s)

Browse

Statistics